Hangzhou Alltest Biotech Past Earnings Performance
Past criteria checks 3/6
Hangzhou Alltest Biotech's earnings have been declining at an average annual rate of -14.8%, while the Medical Equipment industry saw earnings growing at 8% annually. Revenues have been declining at an average rate of 17.8% per year. Hangzhou Alltest Biotech's return on equity is 4.8%, and it has net margins of 25.7%.
Key information
-14.8%
Earnings growth rate
-19.6%
EPS growth rate
| Medical Equipment Industry Growth | 16.0% |
| Revenue growth rate | -17.8% |
| Return on equity | 4.8% |
| Net Margin | 25.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hangzhou Alltest Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 718 | 185 | 125 | 108 |
| 31 Dec 23 | 755 | 181 | 136 | 121 |
| 30 Sep 23 | 938 | -75 | 142 | 138 |
| 30 Jun 23 | 1,053 | -47 | 164 | 173 |
| 31 Mar 23 | 1,526 | 176 | 212 | 197 |
| 31 Dec 22 | 3,389 | 1,184 | 236 | 207 |
| 30 Sep 22 | 3,887 | 1,644 | 234 | 189 |
| 30 Jun 22 | 3,961 | 1,742 | 197 | 157 |
| 31 Mar 22 | 3,684 | 1,665 | 138 | 124 |
| 31 Dec 21 | 1,873 | 766 | 87 | 95 |
| 30 Sep 21 | 1,522 | 784 | 83 | 87 |
| 30 Jun 21 | 1,284 | 690 | 74 | 69 |
| 31 Mar 21 | 1,356 | 797 | 73 | 64 |
| 31 Dec 20 | 1,136 | 679 | 63 | 55 |
| 31 Dec 19 | 241 | 78 | 35 | 36 |
| 31 Dec 18 | 184 | 56 | 20 | 31 |
| 31 Dec 17 | 130 | 34 | 17 | 26 |
| 31 Dec 16 | 76 | 15 | 9 | 20 |
Quality Earnings: 688606 has a high level of non-cash earnings.
Growing Profit Margin: 688606's current net profit margins (25.7%) are higher than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688606's earnings have declined by 14.8% per year over the past 5 years.
Accelerating Growth: 688606's earnings growth over the past year (5.1%) exceeds its 5-year average (-14.8% per year).
Earnings vs Industry: 688606 earnings growth over the past year (5.1%) exceeded the Medical Equipment industry -1.3%.
Return on Equity
High ROE: 688606's Return on Equity (4.8%) is considered low.